[{"data":1,"prerenderedAt":204},["ShallowReactive",2],{"drug-nevirapine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":12,"synonyms":16,"formulations":20,"regimens":35,"contraindications":81,"warnings":91,"renal":99,"monitoring":100,"interactions":101,"review":102,"examples":105,"atc":117,"iran":119,"usApproval":139,"links":145,"populations":161},"nevirapine",1,{"fa":7,"en":8},"نویراپین","Nevirapine","anti-infectives",{"fa":11,"en":11},"NNRTI",[13],{"name":14,"market":15},"Viramune","US",[17,18,7,19],"viramune","ویرامون","NVP",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-200","tablet","oral","200 mg tablet (scored)",{"amount":27,"unit":28,"perUnit":23,"scored":29},200,"mg",true,[15],[32],{"source":33,"section":34},"fda-nevirapine","3",[36,61],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":28,"dose":47,"refs":49,"notes":52},"adult","hiv",{"fa":40,"en":41},"HIV-1 بزرگسال (۱۶ سال به بالا) — ۲۰۰ mg یک بار ۱۴ روز، سپس ۲۰۰ mg دو بار","HIV-1, adults (≥16 y) — 200 mg once daily for 14 days, then 200 mg twice daily",{"minAge":43},{"value":44,"unit":45},16,"year","fixed",{"perDose":27,"dosesPerDay":48},2,[50],{"source":33,"section":51},"2.1",[53],{"text":54,"refs":57},{"fa":55,"en":56},"دوره آغازین ۱۴ روزه حتماً رعایت شود (کاهش راش). اگر در این دوره راش آمد افزایش نده؛ بیش از ۲۸ روز ادامه نده. وقفه بیش از ۷ روز: دوره آغازین از نو. همراه سایر ضدرتروویروس‌ها.","The 14-day lead-in must be followed (fewer rashes). Do not escalate with rash during lead-in; do not extend beyond 28 days. Interruption >7 days: restart lead-in. With other antiretrovirals.",[58,60],{"source":33,"section":59},"2.4",{"source":33,"section":51},{"id":62,"disease":38,"label":63,"population":66,"type":71,"unit":28,"dose":72,"refs":74,"limits":77},"child",{"fa":64,"en":65},"کودک ۱۵ روزه به بالا — ۱۵۰ mg\u002Fm² یک بار ۱۴ روز، سپس ۱۵۰ mg\u002Fm² دو بار (حداکثر ۴۰۰ mg\u002Fروز)","Children ≥15 days — 150 mg\u002Fm² once daily for 14 days, then 150 mg\u002Fm² twice daily (max 400 mg\u002Fday)",{"minAge":67,"maxAge":70},{"value":68,"unit":69},15,"day",{"value":44,"unit":45},"bsa",{"perM2PerDay":73,"dividedDoses":48},300,[75],{"source":33,"section":76},"2.2",{"maxPerDay":78,"refs":79},400,[80],{"source":33,"section":76},[82],{"id":83,"severity":84,"text":85,"refs":88},"ci","block",{"fa":86,"en":87},"نارسایی متوسط یا شدید کبد (Child-Pugh B\u002FC)؛ استفاده در پیشگیری پس از مواجهه (PEP).","Moderate or severe hepatic impairment (Child-Pugh B\u002FC); use in post-exposure prophylaxis (PEP).",[89],{"source":33,"section":90},"4",[92],{"text":93,"refs":96},{"fa":94,"en":95},"هشدار جعبه‌ای: سمیت کبدی کشنده (به‌ویژه ۱۸ هفته اول، زنان و CD4 بالا) و واکنش پوستی کشنده (SJS\u002FTEN) — پایش شدید ۱۸ هفته اول.","Boxed warning: fatal hepatotoxicity (especially first 18 weeks, women and higher CD4) and fatal skin reactions (SJS\u002FTEN) — intensive monitoring for the first 18 weeks.",[97],{"source":33,"section":98},"Boxed Warning",[],[],[],{"status":103,"reviewer":104,"date":104},"unverified",null,[106,111],{"regimen":37,"formulation":22,"input":107,"expect":110},{"ageYears":108,"weightKg":109},35,65,{"perDose":27,"tabletsPerDoseRounded":5},{"regimen":62,"formulation":22,"input":112,"expect":115},{"ageYears":113,"weightKg":44,"heightCm":114},4,100,{"perDose":114,"tabletsPerDoseRounded":116},0.5,[118],"J05AG01",{"status":120,"forms":121,"refs":134},"registered",[122,126,130],{"code":123,"en":124,"fa":125},"05516","NEVIRAPIN 50MG\u002F5ML ORAL SOLUTION","محلول خوراکی نویراپین ۵۰ میلی‌گرم \u002F ۵ میلی‌لیتر",{"code":127,"en":128,"fa":129},"03375","NEVIRAPINE 200MG TAB","قرص نویراپین ۲۰۰ میلی‌گرم",{"code":131,"en":132,"fa":133},"50473","NEVIRAPINE SUSPENSION ORAL 50 mg\u002F5mL 100 mL","سوسپانسیون خوراکی نویراپین ۵۰ میلی‌گرم \u002F ۵ میلی‌لیتر ۱۰۰ میلی‌لیتر",[135],{"source":136,"section":137,"url":138},"darooyab-generic","G-1191\u002FNevirapine","https:\u002F\u002Fwww.darooyab.ir\u002FG-1191\u002FNevirapine",{"kind":140,"refs":141,"id":144},"ANDA",[142],{"source":33,"section":143},"SPL approval \u002F marketing category","ANDA077521",[146,149,153,156,159],{"kind":147,"url":148,"label":144},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=077521",{"kind":150,"url":151,"label":152},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=5f6c3eed-2a5d-46ed-9a7c-59715f338a15","FDA Nevirapine",{"kind":154,"url":155,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa600035.html",{"kind":157,"url":158,"label":118},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J05AG01",{"kind":160,"url":138,"label":8},"darooyab",{"pregnancy":162,"lactation":171,"pediatric":180,"geriatric":188,"reproductive":196},{"level":163,"text":164,"quote":167,"refs":168},"caution",{"fa":165,"en":166},"برچسب: داده‌های رجیستری بارداری (APR) تفاوتی با میزان زمینه‌ای نقص مادرزادی نشان نمی‌دهد.","Label: Antiretroviral Pregnancy Registry data show no difference from the background birth-defect rate.","Available data from the APR show no difference in the risk of overall major birth defects for nevirapine compared with the background rate for major birth defects of 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP).",[169],{"source":33,"section":170},"8.1",{"level":172,"text":173,"quote":176,"refs":177},"avoid",{"fa":174,"en":175},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","… 2) developing viral resistance (in HIV-positive infants), and (3) serious adverse reactions in nursing infants, mothers should not breastfeed if they are receiving nevirapine.",[178],{"source":33,"section":179},"8.2",{"level":163,"text":181,"quote":184,"refs":185},{"fa":182,"en":183},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety, pharmacokinetic profile, and virologic and immunologic responses of nevirapine have been evaluated in HIV-1 infected pediatric subjects aged 3 months to 18 years [see Adverse Reactions (6.1) and Clinical Studies (14.2) ].",[186],{"source":33,"section":187},"8.4",{"level":163,"text":189,"quote":192,"refs":193},{"fa":190,"en":191},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.",[194],{"source":33,"section":195},"8.5",{"level":163,"text":197,"quote":200,"refs":201},{"fa":198,"en":199},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Infertility Limited human data are insufficient to determine the risk of infertility in humans.",[202],{"source":33,"section":203},"8.3",1792444706746]